Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib
hydrochloride in combination with radiofrequency ablation (RFA) and transcatheter arterial
chemoembolization(TACE) in patients with middle-advanced hepatocellular carcinoma(HCC)